Article Archive for December 2009
Taro Pharmaceutical Industries Ltd (OTC:TAROF) has announced that they have begun the Phase 1 of clinical trials in Canada with T2007 which is second in the Company’s class of proprietary non-sedating barbiturate compounds to be …
Somaxon Pharmaceuticals, Inc (NASDAQ:SOMX) has announced that they have scheduled to meet with the US Food and Drug Administration (FDA) on January 20, 2010 to discuss the New Drug Application (NDA) for Silenor which will …
Enzon Pharmaceuticals Inc (NASDAQ:ENZN) has announced that they have set Wednesday, January 27, 2010 as the date of the special meeting of stockholders to vote on the proposed sale of its specialty pharmaceutical business to …
ARCA Biopharma, Inc (NASDAQ:ABIO) has announced that they have submitted a study protocol for review under Food and Drug Administration’s Special Protocol Assessment (SPA) process for the design of a clinical trial to assess the …
Xcorporeal Inc (OTC:XCRP) has announced that they have signed an asset purchase agreement with National Quality Care Inc (NQCI) and Fresenius USA, Inc to sell substantially all of the assets of the Seller to the …
Arrowhead Research Corporation (NASDAQ:ARWR) has announced that they have raised approximately $3.2 million in gross proceeds from a private placement of approximately 6.0 million units.
TheMarketFinancial has initiated an independent bullish technical trading alert on BizAuctions Inc. (OTC:BZCN.OB). Shares of the company finished the day at $0.0018, up 5.88% from the opening bell on heavy buying pressure. The stock reached …
ProtoKinetix Inc (OTC:PKTX) has announced that they have recently been approached by a European biopharma investment group with a series of proposals for development of commercial partnerships in the areas like pharmaceuticals and cosmetics.
Advaxis Inc (OTC:ADXS) has announced that they will be collaborating their Phase 2 trial with the Gynecologic Oncology Group which is a collaborative research of National Cancer Institute.
Emisphere Technologies Inc (OTC:EMIS) has announced that an independent Data Monitoring Committee (DMC) has informed Novartis and its partner Nordic Bioscience about their recommendation to proceed with the Osteoporosis (OP) Phase 3 study and the …
